
    
      This study is a multicenter, randomized Phase 3 study to assess the safety and efficacy of a
      single epidural administration of Resiniferatoxin versus standard of care (SOC) for the
      treatment of intractable pain associated with cancer. Subjects will be followed for 12 weeks
      after treatment.
    
  